Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Ali, Sehrish; Dave, Natasha; Virani, Salim S.; Navaneethan, Sankar D.

doi:10.1007/s11883-019-0794-6

Cited by 27 publications

(20 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [316] Treatment of CKD often includes management of major CVD risk factors (e.g., diabetes mellitus, HTN, cigarette smoking). [ 303 , 317 , 318] Anti-diabetes mellitus drugs having the most favorable renal effects include SGLT2 inhibitors and GLP-1 receptor agonists. [319] In patients with T2DM, both SGLT2 inhibitors and GLP-1 receptor agonists reduce CVD events.…”

Section: Kidney Dysfunctionmentioning

confidence: 99%

“…GLP-1 receptor agonists can reduce urinary albumin excretion, slow kidney disease progression, and reduce CV events. [ 318 , 321] While both reduce the risk of CVD, compared to GLP-1 receptor agonists, SGLT2 inhibitors have a more marked effect on preventing hospitalization for heart failure and reducing kidney disease progression. [320] With the exception of thiazolidinediones and GLP-1 receptor agonists, virtually all anti-diabetes medication classes have representative drugs that require dosing adjustment, depending upon eGFR.…”

Section: Kidney Dysfunctionmentioning

confidence: 99%

“… [351] Sentinel Guidelines and References 2020 Heart Disease and Stroke Statistics – Update: A Report from the American Heart Association [299] 2020 Cardiorenal Protection With the Newer Antidiabetes Agents in Patients with Diabetes and Chronic Kidney Disease: A Statement from the American Heart Association [157] 2019 Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD [325] 2019 Chronic Kidney Disease Diagnosis and Management: A Review. [351] 2019 Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease [318] …”

Section: Kidney Dysfunctionmentioning

confidence: 99%

“…Treatment of CKD often includes management of major CVD risk factors (e.g., diabetes mellitus, HTN, cigarette smoking). [ 303 , 317 , 318] …”

Section: Kidney Dysfunctionmentioning

confidence: 99%

See 3 more Smart Citations

Ten things to know about ten cardiovascular disease risk factors

Bays

Taub

Epstein

et al. 2021

American Journal of Preventive Cardiology

Self Cite

136

View full text Add to dashboard Cite

Given rapid advancements in medical science, it is often challenging for the busy clinician to remain up-to-date on the fundamental and multifaceted aspects of preventive cardiology and maintain awareness of the latest guidelines applicable to cardiovascular disease (CVD) risk factors. The “American Society for Preventive Cardiology (ASPC) Top Ten CVD Risk Factors 2021 Update” is a summary document (updated yearly) regarding CVD risk factors. This “ASPC Top Ten CVD Risk Factors 2021 Update” summary document reflects the perspective of the section authors regarding ten things to know about ten sentinel CVD risk factors. It also includes quick access to sentinel references (applicable guidelines and select reviews) for each CVD risk factor section. The ten CVD risk factors include unhealthful nutrition, physical inactivity, dyslipidemia, hyperglycemia, high blood pressure, obesity, considerations of select populations (older age, race/ethnicity, and sex differences), thrombosis/smoking, kidney dysfunction and genetics/familial hypercholesterolemia. For the individual patient, other CVD risk factors may be relevant, beyond the CVD risk factors discussed here. However, it is the intent of the “ASPC Top Ten CVD Risk Factors 2021 Update” to provide a succinct overview of things to know about ten common CVD risk factors applicable to preventive cardiology.

show abstract

Section: Kidney Dysfunctionmentioning

confidence: 99%

Section: Kidney Dysfunctionmentioning

confidence: 99%

Section: Kidney Dysfunctionmentioning

confidence: 99%

“…Treatment of CKD often includes management of major CVD risk factors (e.g., diabetes mellitus, HTN, cigarette smoking). [ 303 , 317 , 318] …”

Section: Kidney Dysfunctionmentioning

confidence: 99%

See 2 more Smart Citations

Ten things to know about ten cardiovascular disease risk factors

Bays

Taub

Epstein

et al. 2021

American Journal of Preventive Cardiology

Self Cite

136

View full text Add to dashboard Cite

show abstract

“…In the general population, CKD is known to be asso ciated with an increased risk of cardiovascular dis ease (CVD) 76 . There has been debate about the use of febuxostat in people with CVD given the results of the • Does starting allopurinol at a low dose and gradually increasing the dose reduce the risk of flares and thus alleviate the need for flare prophylaxis?…”

Section: Cardiovascular Risk With Xoismentioning

confidence: 99%

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities

et al. 2021

View full text Add to dashboard Cite

Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.

show abstract

Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Glassock

2020

Contemporary Cardiology

View full text Add to dashboard Cite

Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Cited by 27 publications

References 58 publications

Ten things to know about ten cardiovascular disease risk factors

Ten things to know about ten cardiovascular disease risk factors

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities

Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About